[1] Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome[J]. Lancet, 2016,388(10045):717-727. DOI: 10.1016/S0140-6736(16)00339-1.
[2] van den Berg B, Walgaard C, Drenthen J, et al. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis[J]. Nat Rev Neurol, 2014,10(8):469-482. DOI: 10.1038/nrneurol.2014.121.
[3] Rajabally YA. Immunoglobulin and monoclonal antibody therapies in Guillain-Barré syndrome[J]. Neurotherapeutics, 2022,19(3):885-896. DOI: 10.1007/s13311-022-01253-4.
[4] Kuwabara S, Yuki N. Axonal Guillain-Barré syndrome: concepts and controversies[J]. Lancet Neurol, 2013,12(12):1180-1188. DOI: 10.1016/S1474-4422(13)70215-1.
[5] Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome[J]. Lancet, 2021,397(10280):1214-1228. DOI: 10.1016/S0140-6736(21)00517-1.
[6] Doets AY, Lingsma HF, Walgaard C, et al. Predicting outcome in Guillain-Barré Syndrome: international validation of the modified erasmus GBS outcome score[J]. Neurology, 2022,98(5):e518-e532. DOI: 10.1212/WNL.0000000000013139.
[7] Rajabally YA, Uncini A. Outcome and its predictors in Guillain-Barré syndrome[J]. J Neurol Neurosurg Psychiatry, 2012,83(7):711-718. DOI: 10.1136/jnnp-2011-301882.
[8] Zhang G, Li Q, Zhang R, et al. Subtypes and prognosis of Guillain-Barré syndrome in Southwest China[J]. PLoS One, 2015,10(7):e0133520. DOI: 10.1371/journal.pone.0133520.
[9] Wu X, Wu W, Wang Z, et al. More severe manifestations and poorer short-term prognosis of ganglioside-associated Guillain-Barré syndrome in Northeast China[J]. PLoS One, 2014,9(8):e104074. DOI: 10.1371/journal.pone.0104074.
[10] Ye Y, Wang K, Deng F, et al. Electrophysiological subtypes and prognosis of Guillain-Barré syndrome in Northeastern China[J]. Muscle Nerve, 2013,47(1):68-71. DOI: 10.1002/mus.23477.
[11] 中华医学会神经病学分会,中华医学会神经病学分会周围神经病协作组,中华医学会神经病学分会肌电图与临床神经电生理学组,等.中国吉兰‐巴雷综合征诊治指南2019[J]. 中华神经科杂志,2019,52(11):877-882. DOI:10.3760/cma.j.issn.1006‐7876.2019.11.002.
[12] Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome[J]. Ann Neurol, 1998,44(5):780-788. DOI: 10.1002/ana.410440512.
[13] Hughes RA, Newsom-Davis JM, Perkin GD, et al. Controlled trial prednisolone in acute polyneuropathy[J]. Lancet, 1978,2(8093):750-753. DOI: 10.1016/s0140-6736(78)92644-2.
[14] Kleyweg RP, van der Meché FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome[J]. Muscle Nerve, 1991,14(11):1103-1109. DOI: 10.1002/mus.880141111.
[15] Burakgazi AZ, Höke A. Respiratory muscle weakness in peripheral neuropathies[J]. J Peripher Nerv Syst, 2010,15(4):307-313. DOI: 10.1111/j.1529-8027.2010.00293.x.
[16] Ropper AH, Wijdicks EF. Blood pressure fluctuations in the dysautonomia of Guillain-Barré syndrome[J]. Arch Neurol, 1990,47(6):706-708. DOI: 10.1001/archneur.1990.00530060120029.
[17] Chiò A, Cocito D, Leone M, et al. Guillain-Barré syndrome: a prospective, population-based incidence and outcome survey[J]. Neurology, 2003,60(7):1146-1150. DOI: 10.1212/01.wnl.0000055091.96905.d0.
[18] Hughes RA, Hadden RD, Rees JH, et al. The prognosis and main prognostic indicators of Guillain-Barré syndrome: a multicentre prospective study of 297 patients[J]. Brain, 1998, 121 Pt 4:767-769. DOI: 10.1093/brain/121.4.767.
[19] Cornblath DR, Mellits ED, Griffin JW, et al. Motor conduction studies in Guillain-Barré syndrome: description and prognostic value[J]. Ann Neurol, 1988,23(4):354-359. DOI: 10.1002/ana.410230407.
[20] Yuki N, Hartung HP. Guillain-Barré syndrome[J]. N Engl J Med, 2012,366(24):2294-2304. DOI: 10.1056/NEJMra1114525.
[21] Hughes RA, Cornblath DR. Guillain-Barré syndrome[J]. Lancet, 2005,366(9497):1653-1666. DOI: 10.1016/S0140-6736(05)67665-9.
[22] Hadden RD, Karch H, Hartung HP, et al. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome[J]. Neurology, 2001,56(6):758-765. DOI: 10.1212/wnl.56.6.758.
[23] Nithyashree N, Dhanaraj M, Kumar S, et al. Factors predicting poor outcome in patients with fulminant Guillaine-Barré syndrome[J]. Ann Indian Acad Neurol, 2014,17(4):463-465. DOI: 10.4103/0972-2327.144040.
[24] Hughes RA, Swan AV, Raphaël JC, et al. Immunotherapy for Guillain-Barré syndrome: a systematic review[J]. Brain, 2007,130 Pt 9:2245-2257. DOI: 10.1093/brain/awm004.
[25] Uncini A, Manzoli C, Notturno F, et al. Pitfalls in electrodiagnosis of Guillain-Barré syndrome subtypes[J]. J Neurol Neurosurg Psychiatry, 2010,81(10):1157-1163. DOI: 10.1136/jnnp.2010.208538.
[26] Uncini A, Kuwabara S. The electrodiagnosis of Guillain-Barré syndrome subtypes: where do we stand?[J]. Clin Neurophysiol, 2018,129(12):2586-2593. DOI: 10.1016/j.clinph.2018.09.025.
[27] Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in Northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies[J]. Brain,1995,118 Pt 3:597-605. DOI: 10.1093/brain/118.3.597.
[28] Dhar R, Stitt L, Hahn AF. The morbidity and outcome of patients with Guillain-Barré syndrome admitted to the intensive care unit[J]. J Neurol Sci, 2008,264(1-2):121-128. DOI: 10.1016/j.jns.2007.08.005.
[29] van Koningsveld R, Steyerberg EW, Hughes RA, et al. A clinical prognostic scoring system for Guillain-Barré syndrome[J]. Lancet Neurol, 2007,6(7):589-594. DOI: 10.1016/S1474-4422(07)70130-8.
[30] Walgaard C, Lingsma HF, Ruts L, et al. Early recognition of poor prognosis in Guillain-Barré syndrome[J]. Neurology, 2011,76(11):968-975. DOI: 10.1212/WNL.0b013e3182104407.
[31] Yang J, Jia L. Predictors for mechanical ventilation and short-term prognosis in patients with Guillain-Barré syndrome[J]. Crit Care, 2015,19:407. DOI: 10.1186/s13054-015-1123-2.
[32] Khan F, Pallant JF, Ng L, et al. Factors associated with long-term functional outcomes and psychological sequelae in Guillain-Barré syndrome[J]. J Neurol, 2010,257(12):2024-2031. DOI: 10.1007/s00415-010-5653-x.
[33] Weiss H, Rastan V, Müllges W, et al. Psychotic symptoms and emotional distress in patients with Guillain-Barré syndrome[J]. Eur Neurol, 2002,47(2):74-78. DOI: 10.1159/000047956.
|